Pitolisant, sold as Wakix, is a wakefulness-promoting medication that works through histamine receptors rather than dopamine. By blocking the H3 histamine autoreceptor (which normally puts a brake on histamine release), it increases brain histamine. FDA-approved for narcolepsy. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Histamine H3 receptor inverse agonist/antagonist with secondary sigma-1 receptor agonism and wake-promoting eugeroic activity
A first-in-class non-imidazole piperidine derivative developed at Bioprojet as a selective histamine H3 receptor inverse agonist, approved for narcolepsy-associated excessive daytime sleepiness and cataplexy, and distinguished from conventional stimulants by histaminergic wake promotion without dopaminergic reinforcement or controlled-substance classification.
Abstract
Pitolisant (BF2.649, Wakix) is the first histamine H3 receptor inverse agonist/antagonist to achieve regulatory approval, authorized by the European Medicines Agency in March 2016 and by the United States Food and Drug Administration in August 2019 for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The compound is a non-imidazole piperidine derivative, chemically designated 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride, that binds the human histamine H3 receptor with sub-nanomolar affinity (Ki approximately 0.3 to 1.0 nM) and functions as a potent inverse agonist at the constitutively active receptor with an EC50 of approximately 1.5 nM [1, 2]. By antagonizing presynaptic H3 autoreceptors on tuberomamillary histaminergic neurons, pitolisant enhances endogenous histamine synthesis and release, thereby activating downstream wake-promoting circuitry including noradrenergic, dopaminergic, and cholinergic projection systems, without direct dopaminergic reinforcement in the nucleus accumbens [3, 4]. This mechanistic distinction from amphetamine, modafinil, and solriamfetol is the pharmacological basis for the compound’s classification as a non-controlled substance in both the United States and the European Union, a clinically meaningful regulatory differentiation in a therapeutic area historically dominated by Schedule II and Schedule IV agents. The clinical evidence base for pitolisant in narcolepsy rests on the HARMONY trial program: HARMONY 1 demonstrated statistically significant reduction in Epworth Sleepiness Scale scores versus placebo (Cohen’s d 0.61) and significant reduction in weekly cataplexy rate (62% versus 8% for placebo) [5, 6]; HARMONY CTP confirmed anti-cataplectic efficacy with a Cohen’s d of 0.86 and a 75% reduction in weekly cataplexy rate versus 38% for placebo [7]; and HARMONY III established long-term safety and efficacy over 12 months of continuous dosing [8]. The FDA subsequently expanded the indication to include cataplexy in adults with narcolepsy (October 2020) and both excessive daytime sleepiness and cataplexy in pediatric patients aged 6 years and older (2024 and February 2026, respectively) [9]. Beyond narcolepsy, the HAROSA trial program has demonstrated efficacy for residual excessive daytime sleepiness in obstructive sleep apnea, with statistically significant ESS reductions at both 20 mg and 40 mg doses [10, 11]. Exploratory clinical and preclinical investigations extend to epilepsy, Prader-Willi syndrome, Parkinson’s disease-associated sleepiness, cognitive impairment, and obesity. Pharmacokinetics are characterized by high oral bioavailability (approximately 90%), rapid absorption with peak plasma concentrations at approximately 3 hours, plasma protein binding of 91 to 96%, and hepatic metabolism primarily via CYP2D6 and secondarily via CYP3A4, producing inactive metabolites conjugated with glycine or glucuronic acid [12]. The elimination half-life is 10 to 12 hours in most published pharmacokinetic analyses, though some reports note a range extending to 20 hours depending on the analytical methodology and population studied. CYP2D6 poor metabolizers exhibit approximately 2.4-fold increases in area under the curve, necessitating dose adjustment to a maximum of 17.8 mg daily in this population. The compound is well tolerated at approved doses of 8.9 to 35.6 mg daily; the principal adverse events are headache, insomnia, and nausea, with dose-dependent incidence [13]. QT interval prolongation is identified in the prescribing label, and the compound should be used with caution in patients with known QT prolongation or concurrent QT-prolonging medications. This monograph reviews the chemistry, synthesis, receptor pharmacology, pharmacokinetics, preclinical pharmacology, clinical evidence base across all studied indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five alternative wake-promoting or histamine-modulating agents against pitolisant on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.